Data for: Randomized trial of neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER+/HER2- breast cancer (PREDIX LumB): Primary analysis and development of the CDKPredX metagene predictor
Documentation files
Documentation files
Citation and access
Citation and access
Data access level:
Creator/Principal investigator(s):
Research principal:
Data contains personal data:
Yes
Type of personal data:
The dataset does not contain direct identifiers such as names, social security numbers, or contact details. Each patient is represented by a trial-specific ID. The trial-specific IDs are pseudonymized and cannot be used to identify individual patients. Linkage to individual identities is only possible by the local principal investigator and designated site staff through site-specific keys, which are not shared. The metadata include gender and treatment arm, which are indirect identifiers. The sequencing data (FASTQ files from WES and RNA-Seq) represent molecular profiles, which qualify as sensitive health-related data. Although pseudonymized, genomic data are inherently identifiable and are protected under regulations for genetic and health data.
Code key exists:
Yes
Sensitive personal data:
Yes
